LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) insider Trent Kamke sold 2,928 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the completion of the transaction, the insider directly owned 3,749 shares in the company, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
LeMaitre Vascular Price Performance
Shares of LMAT traded down $6.30 on Monday, hitting $101.64. The company’s stock had a trading volume of 410,363 shares, compared to its average volume of 209,885. The company has a market capitalization of $2.32 billion, a PE ratio of 37.51, a PEG ratio of 3.00 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. LeMaitre Vascular, Inc. has a fifty-two week low of $78.35 and a fifty-two week high of $118.01. The company has a 50 day moving average price of $110.00 and a 200 day moving average price of $94.48.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.LeMaitre Vascular’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts anticipate that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.
LeMaitre Vascular Dividend Announcement
Analyst Ratings Changes
LMAT has been the topic of several recent analyst reports. Citizens Jmp boosted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Barrington Research boosted their target price on LeMaitre Vascular from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Wells Fargo & Company boosted their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Finally, Roth Mkm restated a “buy” rating and issued a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.
Get Our Latest Stock Analysis on LeMaitre Vascular
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Sound Income Strategies LLC boosted its position in LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 183 shares during the last quarter. Cornerstone Planning Group LLC boosted its position in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares during the last quarter. Catalyst Capital Advisors LLC bought a new position in LeMaitre Vascular in the 1st quarter valued at $32,000. MAI Capital Management bought a new position in LeMaitre Vascular in the 3rd quarter valued at $38,000. Finally, First Horizon Corp bought a new position in LeMaitre Vascular in the 3rd quarter valued at $39,000. 84.64% of the stock is currently owned by institutional investors.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
Featured Articles
- Five stocks we like better than LeMaitre Vascular
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
